First AD

Second AD

Dr Lamanna Shares Perspectives on EHA 2024 Data for the 2G BCL2 Inhibitors in R/R CLL 

Video content above is prompted by the following:

Briefly share perspective/insights on emerging novel agents in R/R CLL: 2nd gen BCL2 inhibitors 

Chronic Lymphocytic Leukemia

 Chronic Lymphocytic Leukemia condition center page is a comprehensive resource for clinical news and expert insights on treatment advances and ongoing research in chronic lymphocytic leukemia. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs and updates with chronic lymphocytic leukemia therapy. 

OncLive Peer Exchange® 

® Peer Exchange video program comprises lively expert panel discussions feature peer-to-peer exchanges providing authoritative insights, opinions, and perspectives on important issues facing today’s health care professionals. Episodes focus on updates and insights across solid and hematologic malignancies, including breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, gynecological cancers, and hematologic malignancies. 

EHA 2024: Updates in the Treatment of CLL   

Peer Exchange

UCI Health Chao Family Comprehensive Cancer Center

Cancer Centers

Partner

Dana-Farber Cancer Institute

Mayo Clinic

Columbia University Herbert Irving Comprehensive Cancer Center

City of Hope

Nicole Lamanna, MD, offers expert insights on the emerging data for second-generation BCL2 inhibitors in relapsed/refractory chronic lymphocytic leukemia, highlighting recent advancements in the field. 

Introducing the Expert Panel on CLL Treatment Updates Live at EHA 2024   

Testing Practices and Role of High-risk Features to Decision Making in Newly Diagnosed CLL 

Frontline BTKi Selection 

Dr Parrondo’s Frontline CLL Treatment Approach for Pre-existing HTN and Afib 

Dr Lamanna Reviews Study Data for 1L Doublet Therapy or Triplet Therapy 

Dr Danilov Reviews EHA 2024 Data on the Role of 1L Triplet Therapy in CLL 

EHA 2024 Review of Ongoing Trials Evaluating BCL2i/BTKi Combination Approaches 

Navigating Treatment Approaches for R/R CLL 

How Experts View MAIC Data That was Presented at EHA 2024   

BTKi Intolerance in Real-world Practice & Management Strategy 

Applying EHA 2024 Data to Switching and Sequencing Treatments for CLL & Impact of Toxicities   

Approach to Hypertension Management With BTKi Treatment 

Dr Parrondo shares Approach to Managing BTKi Treatment-Related Afib  

Navigating BTKi Resistance in CLL with Findings from ELEVATE-RR and ALPINE Studies: Sequencing Approach and Potential Role for Testing  

Experts Review Pirtobrutinib Clinical Data and Share its Utilization in Practice